Systemic biological, anti-cytokine agents show a significant improvement of symptoms of depression in patients with chronic inflammatory disorders, specifically targeting IL-6 (tocilizumab) or TNF-α (adalimumab, etanercept, infliximab) [Kappelmann et al., 2018]. The gene discussed is IL6; the disease is depressive symptom measurement.